Biotech Firm Pits Its Actives Against Leading Skin Lighteners On Market
This article was originally published in The Rose Sheet
Executive Summary
Unlike skin-lightening ingredient arbutin, which releases potentially carcinogenic hydroquinone, Sirona Biochem Corp.’s TFC-849 and TFC-723 compounds are stable and do not break down in the body. They’re more effective tyrosinase inhibitors as well, the Canadian biotech firm says.
You may also be interested in...
FDA Proposal Classifies Skin Bleaching Products As Drugs
FDA is proposing a rule that classifies all over-the-counter skin bleaching products as drugs requiring an approved new drug application, the agency announced in a notice of proposed rulemaking published in an Aug. 29 Federal Register 1notice
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.